Nanjing Leads Biolabs Co Ltd
9887.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.06B
Close$
$5.72
86.4% downside
Current Fair Value
86.4% downsideOvervalued by 86.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.06 Billion |
|---|---|
| Enterprise Value | $8.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.35 |
| Beta | 1.43 |
| Outstanding Shares | 197,032,246 |
Return
| Return on Equity | -29.18% |
|---|---|
| Return on Assets | -17.65% |
| Return on Invested Capital | -24.02% |
Valuation & Multiples
| P/E Ratio | -28.11 |
|---|---|
| PEG | -4.03 |
| Price to Sales | 41.94 |
| Price to Book Ratio | 10.49 |
| Enterprise Value to Revenue | 37.05 |
| Enterprise Value to EBIT | -37.93 |
| Enterprise Value to Net Income | -32 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 29, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanjing Leads Biolabs Co Ltd
244 employees
CEO: Xiaoqiang Kang Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's thera...